FILINGS
| AZNCF 0000901832 | |||
|---|---|---|---|
| Filing Date | Form Type | Description | Document |
| 2026-02-03 | 6-K | UPDATE ON SAPHNELO SUBCUTANEOUS ADMINISTRATION | View Document |
| 2026-02-02 | S-8 | FORM S-8 | View Document |
| 2026-02-02 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2026-02-02 | 6-K | IMFINZI RECOMMENDED IN EU FOR EARLY GASTRIC CANCER | View Document |
| 2026-02-02 | 6-K | ASTRAZENECA BEGINS TRADING ON NYSE | View Document |
| 2026-01-30 | 25 | FORM 25 | View Document |
| 2026-01-30 | 6-K | ASTRAZENECA AGREES OBESITY AND T2D DEAL WITH CSPC | View Document |
| 2026-01-29 | 6-K | ASTRAZENECA INVESTS $15BN IN CHINA THROUGH 2030 | View Document |
| 2026-01-22 | CERT | NYSE CERTIFICATION | View Document |
| 2026-01-22 | 8-A12B | 8-A12B | View Document |
| 2026-01-22 | CERT | NYSE CERTIFICATION | View Document |
| 2026-01-22 | 8-A12B | 8-A12B | View Document |
| 2026-01-20 | 6-K | ASTRAZENECA TO COMPLETE DIRECT LISTING ON NYSE | View Document |
| 2026-01-08 | 6-K | AZN NEW HEAD OF INVESTOR RELATIONS JORIS SILON | View Document |
| 2026-01-02 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2025-12-22 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-12-22 | 6-K | ENHERTU GRANTED BTD FOR POST-NEOADJUVANT EARLY BC | View Document |
| 2025-12-22 | 6-K | UPDATE ON LATIFY PHASE III TRIAL OF CERALASERTIB | View Document |
| 2025-12-19 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-12-16 | 6-K | SUBCUTANEOUS SAPHNELO APPROVED IN EU | View Document |
| 2025-12-16 | 6-K | ENHERTU APPROVED IN US FOR 1L HER2+ METASTATIC BC | View Document |
| 2025-12-04 | 6-K | HOLDING(S) IN COMPANY | View Document |
| 2025-12-01 | 6-K | BLOCK LISTING INTERIM REVIEW | View Document |
| 2025-12-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2025-11-26 | 6-K | IMFINZI APPROVED IN US FOR EARLY GASTRIC CANCER | View Document |
| 2025-11-24 | 6-K | ASTRAZENECA MANUFACTURING INVESTMENT IN MARYLAND | View Document |
| 2025-11-20 | 6-K | KOSELUGO (SELUMETINIB) APPROVED IN THE US | View Document |
| 2025-11-17 | 6-K | HOLDING(S) IN COMPANY | View Document |
| 2025-11-14 | 25-NSE | View Document | |
| 2025-11-14 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-11-12 | 144 | View Document | |
| 2025-11-10 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-11-06 | 6-K | 9M AND Q3 2025 RESULTS | View Document |
| 2025-11-03 | 6-K | RESULT OF GENERAL MEETING | View Document |
| 2025-11-03 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2025-11-03 | 6-K | FORM 6-K | View Document |
| 2025-10-28 | 6-K | DIRECTOR DECLARATION | View Document |
| 2025-10-28 | 6-K | KOSELUGO (SELUMETINIB) APPROVED IN THE EU | View Document |
| 2025-10-22 | 6-K | TEZSPIRE APPROVED IN EU FOR CRSWNP | View Document |
| 2025-10-20 | 6-K | US FDA APPROVES TEZSPIRE IN CRSWNP | View Document |
| 2025-10-20 | 6-K | POSITIVE CHMP OPINION FOR SUBCUTANEOUS SAPHNELO | View Document |
| 2025-10-14 | 6-K | AGREEMENT WITH US GOVT TO LOWER MEDICINE PRICES | View Document |
| 2025-10-07 | 6-K | BAXDROSTAT MET PRIMARY ENDPOINT IN BAX24 PH3 TRIAL | View Document |
| 2025-10-06 | 6-K | DATROWAY IMPROVED OS AND PFS IN TROPION-BREAST02 | View Document |
| 2025-10-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2025-09-29 | 6-K | ENHERTU IMPROVED IDFS IN EARLY BC IN DB-05 | View Document |
| 2025-09-29 | 6-K | AZN HARMONISES LISTING STRUCTURE | View Document |
| 2025-09-29 | 6-K | 6-K | View Document |
| 2025-09-25 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-09-22 | 6-K | KOSELUGO RECOMMENDED FOR EU APPROVAL | View Document |
| 2025-09-22 | 6-K | TEZSPIRE RECOMMENDED FOR APPROVAL IN EU FOR CRSWNP | View Document |
| 2025-09-17 | 6-K | SAPHNELO MET PRIMARY ENDPOINT IN TULIP-SC | View Document |
| 2025-09-17 | 6-K | UPDATE ON RESOLUTE PHASE III TRIAL | View Document |
| 2025-09-02 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2025-08-28 | 6-K | HOLDING(S) IN COMPANY | View Document |
| 2025-08-26 | 6-K | HOLDING(S) IN COMPANY | View Document |
| 2025-08-21 | 6-K | HOLDING(S) IN COMPANY | View Document |
| 2025-08-18 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-08-15 | 6-K | HOLDING(S) IN COMPANY | View Document |
| 2025-08-12 | 6-K | HOLDING(S) IN COMPANY | View Document |
| 2025-08-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2025-07-29 | 6-K | FORM 6-K | View Document |
| 2025-07-24 | 6-K | GEFURULIMAB NANOBODY MET PHASE III ENDPOINTS | View Document |
| 2025-07-22 | 6-K | ASTRAZENECA PLANS TO INVEST $50BN IN THE US | View Document |
| 2025-07-16 | 6-K | UPDATE ON ANSELAMIMAB IN AL AMYLOIDOSIS | View Document |
| 2025-07-14 | 6-K | BAXDROSTAT MET PRIMARY ENDPT IN BAXHTN PHIII TRIAL | View Document |
| 2025-07-07 | 6-K | IMFINZI APPROVED IN THE EU FOR BLADDER CANCER | View Document |
| 2025-07-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2025-06-26 | 11-K | FORM 11-K | View Document |
| 2025-06-24 | 6-K | DATROWAY APPROVED IN US FOR EGFRM LUNG CANCER | View Document |
| 2025-06-13 | 6-K | ASTRAZENECA ENTERS INTO COLLABORATION WITH CSPC | View Document |
| 2025-06-12 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-06-06 | 6-K | FIXED-DURATION CALQUENCE APPROVED IN EU FOR 1L CLL | View Document |
| 2025-06-02 | 6-K | BLOCK LISTING INTERIM REVIEW | View Document |
| 2025-06-02 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2025-05-27 | 6-K | IMFINZI RECOMMENDED IN EU FOR BLADDER CANCER | View Document |
| 2025-05-23 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-05-21 | 6-K | DIRECTOR DECLARATION | View Document |
| 2025-05-20 | 6-K | ACQUISITION OF ESOBIOTEC COMPLETED | View Document |
| 2025-05-09 | 6-K | IMFINZI IMPROVED DFS IN EARLY BLADDER CANCER | View Document |
| 2025-05-07 | 6-K | ENHERTU IMPROVED PCR IN EARLY-STAGE BREAST CANCER | View Document |
| 2025-05-06 | 6-K | CALQUENCE COMBINATION APPROVED IN EU FOR 1L MCL | View Document |
| 2025-05-02 | 6-K | BREZTRI MET PRIMARY ENDPOINTS IN PH3 ASTHMA TRIALS | View Document |
| 2025-05-01 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-05-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2025-04-29 | 6-K | FIXED-DURATION CALQUENCE RECOMMENDED IN EU FOR CLL | View Document |
| 2025-04-29 | 6-K | UPDATE ON CAPITELLO-280 PHASE III TRIAL | View Document |
| 2025-04-29 | 6-K | 1ST QUARTER RESULTS | View Document |
| 2025-04-23 | SCHEDULE 13G/A | View Document | |
| 2025-04-22 | 6-K | ENHERTU COMBINATION IMPROVED PFS IN 1L HER2+ MBC | View Document |
| 2025-04-11 | 6-K | RESULT OF AGM | View Document |
| 2025-04-10 | SCHEDULE 13G/A | View Document | |
| 2025-04-04 | 6-K | IMFINZI APPROVED IN EU FOR AEGEAN | View Document |
| 2025-04-04 | 6-K | ENHERTU APPROVED IN EU IN POST-ET BREAST CANCER | View Document |
| 2025-04-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2025-03-31 | 6-K | CALQUENCE RECOMMENDED FOR EU APPROVAL IN 1L MCL | View Document |
| 2025-03-31 | 6-K | IMFINZI APPROVED IN THE US FOR BLADDER CANCER | View Document |
| 2025-03-21 | 6-K | AZN INVESTS $2.5BN IN BEIJING R&D & MANUFACTURING | View Document |
| 2025-03-17 | 6-K | ENEBOPARATIDE PHASE III TRIAL MET PRIMARY ENDPOINT | View Document |
| 2025-03-17 | 6-K | IMFINZI APPROVED IN EU FOR LIMITED-STAGE SCLC | View Document |
Search company filings and access detailed reports including 10-K, 10-Q, 8-K, and other critical filings. Stay informed on corporate disclosures, regulatory filings, and updates with our easy-to-use EDGAR API filings search tool.
